Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

Journal of the National Cancer Institute

Volumn 95, Issue 15, 2003, Pages 1128-1137

  Nardelli Haefliger, Denise ^a   Wirthner, Daniel ^a   Schiller, John T ^b   Lowy, Douglas R ^b   Hildesheim, Allan ^b   Ponci, Françoise ^a   De Grandi, Pierre ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NOVAVAX; ORAL CONTRACEPTIVE AGENT; TETANUS TOXOID; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONDYLOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LUTEAL PHASE; MENSTRUAL CYCLE; NONPARAMETRIC TEST; OVULATION; PAPANICOLAOU TEST; PRIORITY JOURNAL; SEROCONVERSION; SEROTYPE; STATISTICAL SIGNIFICANCE; UTERINE CERVIX; UTERINE CERVIX MUCUS; VIRUS PARTICLE; WART VIRUS; IMMUNOLOGY; PAPILLOMA VIRUS; VIRION;

ANTIBODIES, VIRAL; CERVIX UTERI; CONTRACEPTIVES, ORAL, HORMONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENSTRUAL CYCLE; OVULATION; PAPILLOMAVIRIDAE; VIRAL VACCINES; VIRION;

EID: 0041920776     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg018     Document Type: Article

References (42)

1. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
2. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 1979;122:1892-8.
3. Parr EL, Parr MB. A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid. J Reprod Fertil 1990;89:619-25.
4. Mestecky J, Kutteh WH, Jackson S. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10 Suppl 2:S11-20.
5. Brandtzaeg P. Mucosal immunity in the female genital tract. J Reprod Immunol 1997;36:23-50.
6. Hocini H, Barra A, Belec L, Iscaki S, Preud'homme JL, Pillot J, et al. Systemic and secretory humoral immunity in the normal human vaginal tract. Scand J Immunol 1995;42:269-74.
7. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997;65: 1387-94.
8. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998;72:8220-9.
9. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999;73:9609-13.
10. Decroix N, Hocini H, Quan CP, Bellon B, Kazatchkine MD, Bouvet JP. Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand J Immunol 2001;53:401-9.
11. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci U S A 1996;93:11414-20.
12. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17:1681-9.
13. Parr EL, Parr MB. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 1997;71:8109-15.
14. Bouvet JP, Belec L, Pires R, Pillot J. Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infect Immun 1994; 62:3957-61.
15. Crowley-Nowick PA, Bell MC, Brockwell R, Edwards RP, Chen S, Partridge EE, et al. Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immunol 1997;17:370-9.
16. McDermott MR, Clark DA, Bienenstock J. Evidence for a common mucosal immunologic system. II. Influence of the estrous cycle on B immunoblast migration into genital and intestinal tissues. J Immunol 1980;124: 2536-9.
17. Wira CR, Rossoll RM. Antigen-presenting cells in the female reproductive tract: influence of the estrous cycle on antigen presentation by uterine epithelial and stromal cells. Endocrinology 1995;136:4526-34.
18. Parr TB, Johnson TA, Silberstein LE, Kipps TJ. Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur J Immunol 1994;24:2941-9.
19. Sullivan DA, Wira CR. Hormonal regulation of immunoglobulins in the rat uterus: uterine response to multiple estradiol treatments. Endocrinology 1984;114:650-8.
20. Tauber PF, Cramer GM, Zaneveld LJ. Effect of the intrauterine contraceptive device on protein components of human uterine fluid. Contraception 1993;48:494-512.
21. Schumacher MJ, Mitchell GF. Inhibition of murine reaginic antibody responses by nasal immunotherapy with modified allergen. Int Arch Allergy Appl Immunol 1980;62:382-8.
22. Usala SJ, Usala FO, Haciski R, Holt JA, Schumacher GF. IgG and IgA content of vaginal fluid during the menstrual cycle. J Reprod Med 1989; 34:292-4.
23. Kutteh WH, Prince SJ, Hammond KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996;104: 538-42.
24. Hildesheim A, McShane LM, Schiffman M, Bratti MC, Rodriguez AC, Herrero R, et al. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cell collection instrument and correlates of immune measures. J Immunol Methods 1999;225:131-43.
25. Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999;42:93-106.
26. Lowy D, Howley P. Papillomaviruses. In: Knipe D, Howley P, Griffin D, editors. Fields virology. Vol 2. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. p. 2231-64.
27. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
28. Schiller JT, Hidesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000;19:67-74.
29. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995;92:11553-7.
30. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.
31. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
32. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-5.
33. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284-92.
34. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001;167: 5420-8.
35. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184:1183-6.
36. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Med 2002;347:1645-51.
37. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996;70:5875-83.
38. Quesnel A, Cu-Uvin S, Murphy D, Ashley RL, Flanigan T, Neutra MR. Comparative analysis of methods for collection and measurement of immunoglobulins in cervical and vaginal secretions of women. J Immunol Methods 1997;202:153-61.
39. Kutteh WH, Hatch KD, Blackwell RE, Mestecky J. Secretory immune system of the female reproductive tract: I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol 1988;71:56-60.
40. Nowicki S, Tassell AH, Nowicki B. Susceptibility to gonococcal infection during the menstrual cycle. JAMA 2000;283:1291-2.
41. Cottingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use: a quantitative review. Genitourin Med 1992;68:209-16.
42. Spinillo A, Gorini G, Piazzi G, Baltaro F, Monaco A, Zara F. The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Contraception 1996;54:163-8.